Skip to main content
Navigate Up
Sign In
 

Why Tom Price’s Biotech Stock Has Medical Ethicists Worried


​As Senate Democrats grilled Rep. Tom Price (R-Ga.) at his confirmation hearing Wednesday over concerns that his trading in health care company stock violated congressional ethics regulations, medical ethicists say Price’s personal investments could pose a conflict of interest considering his role as a doctor.
 
President Donald Trump’s nominee for health and human services secretary, is, after all, an orthopedic surgeon ― and physicians, as well as people who work for pharmaceutical, biotech and device companies, commit to codes of ethics to serve the patient and public health interest first, not the interest of a company or any one individual.
 
During his confirmation hearing, Price maintained that “everything I did was ethical, above-board legal and transparent.” His team did not immediately reply to a request for comment from The Huffington Post. 
 
Yet Price has faced plenty of scrutiny for his personal financial interests: Critics say legislation he worked on had the potential to directly affect his investments, and a report last week revealed he may have gotten a sweetheart deal from the Australian biotech firm Innate Immunotherapeutics for stocks that have since experienced a 400 percent gain.